News Room

Julie Swann, a professor of industrial and systems engineering at North Carolina State University, who advised the CDC during the H1N1 response, said she believes North Carolina will have all of the necessary logistics in place for mass distribution of a coronavirus vaccine as soon as one if approved.

The U.S. just reached a dark milestone: 10 million reported coronavirus cases. But there is also big news for a potential coronavirus vaccine. On November 9, Pfizer and German drugmaker BioNTech announced that data from their ongoing coronavirus vaccine trial shows the vaccine is more than 90% effective in preventing COVID-19, per the New York Times.

The duo's vaccine, known as BNT162b2, proved to be 90% effective after being tested on nearly 44,000 participants in its Phase III study.  This is a significant milestone in the fight against a virus that has infected more than 50 million people around the globe, resulting in over 1.2 million deaths. FOX Business takes a look at the key data points investors and consumers should know, as well as reactions from business and political leaders.

Prashant Yadav of the Center for Global Development and Tinglong Dai of Johns Hopkins University, join “Squawk on the Street” to discuss coronavirus vaccine development and distribution.

As Thanksgiving approaches, millions of Americans are weighing the risk of pandemic travel against the yearning to visit friends and family. But one group seems all but certain to be heading home in large numbers just in time for turkey and holiday gatherings: college students. Since the start of the fall semester, most universities have planned to end in-person classes before Thanksgiving and require students to finish the term remotely, partly to avoid an expected wave of cold-weather infections. That means that in a couple of weeks, hundreds of thousands of students will be streaming back to hometowns until the spring semester begins.